In recent years, several case series have been published demonstrating high efficacy and good tolerability for daratumumab intervention in several treatment-refractory autoimmune diseases, with a role emerging for anti-CD38 antibody therapy (51, 52). Here, CD38 is linked to autoimmune disease.